Phaseline

Targets › LMP1

LMP1: drug programs, companies and trials

3 programs from 2 companies in 5 trials: 5 Phase 1; Oncology, Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on LMP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineEBV-specific T cells: A (LMP, BARF1 and EBNA1 specific CTLs)
EBV-specific cytotoxic T lymphocytes targeting viral antigens LMP1, LMP2, BARF1, and EBNA1
LMP1, LMP2, BARF1, EBNA1Phase 1Hodgkin's DiseaseMar 2027
ModernaTXmRNA-1189
mRNA vaccine encoding Epstein-Barr virus antigens
EBNA1, LMP1, BZLF1Phase 1Epstein-Barr Virus Infection; Epstein-Barr VirusMay 2027
Baylor College of MedicineMABEL CTLs
EBV-specific cytotoxic T lymphocytes targeting LMP, BARF-1 and EBNA1 viral antigens
LMP1, BARF1, EBNA1Phase 1Hodgkin DiseaseMar 2029

Conditions

Epstein-Barr Virus Infection (2) Epstein-Barr Virus (1) Hodgkin Disease (1) Hodgkin's Disease (1)

Modalities

other (2), mixed (1)

Companies

Baylor College of Medicine (2) ModernaTX (1)

Related targets

EBNA1 (3) BARF1 (2) BZLF1 (1) LMP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.